

IN THE CLAIMS

1-61 (canceled)

62. (currently amended) A method for suppressing tumor growth in a mammal comprising: administering to a mammal a replication competent, target tumor cell-specific adenovirus, said adenovirus comprising an adenoviral gene essential for replication under transcriptional control of a prostate-specific antigen (PSA)-TRE wherein said target tumor cell-specific adenovirus results in virus replication-dependent cytolysis; and

at least one antineoplastic agent selected from the group consisting of etoposide, paclitaxel, docetaxel and doxorubicin, at a dose less than the effective dose for suppressing tumor growth when administered alone,

wherein said tumor growth is suppressed.

63. (previously presented) The method of claim 62, wherein said at least one antineoplastic agent is selected from the group consisting of paclitaxel, docetaxel and etoposide.

64-71. (canceled)

72. (previously presented) The method of claim 80, wherein the adenoviral early gene is E1A.

73. (previously presented) The method of claim 80, wherein the adenoviral early gene is E1B.

74. (previously presented) The method of claim 73, wherein E1B has a deletion of the 19-kDa region.

75-76. (canceled)

77. (previously presented) A method for suppressing tumor growth in a mammal comprising: administering to a mammal a synergistic combination of a replication competent, target tumor cell-specific adenovirus, said adenovirus comprising an adenoviral gene essential for replication under transcriptional control of a prostate-specific antigen

(PSA)-TRE wherein said target tumor cell-specific adenovirus results in virus replication-dependent cytolysis; and

at least one antineoplastic agent selected from the group consisting of etoposide, estramustin, paclitaxel, docetaxel and doxorubicin, in a combined dosage effective to substantially reduce the numbers of said targeted solid tumor cell population,

wherein said tumor growth in said mammal is suppressed.

78. (previously presented) The method according to Claim 77, wherein said adenovirus is administered by site-specific injection.

79. (previously presented) The method according to Claim 77, wherein said adenovirus is administered by intravenous injection.

80. (previously presented) The method according to Claim 77, wherein said adenoviral gene essential for replication is an adenoviral early gene.

81. (currently amended) The method of claim 80 ~~62~~, wherein the adenoviral early gene is E1A.

82. (currently amended) The method of claim 80 ~~62~~, wherein the adenoviral early gene is E1B.

83. (previously presented) The method of claim 82, wherein E1B has a deletion of the 19-kDa region.

84. (previously presented) The method according to Claim 62, wherein said adenovirus is administered by site-specific injection.

85. (previously presented) The method according to Claim 62, wherein said adenovirus is administered by intravenous injection.

# REMARKS

In view of the above amendments and the following remarks, the Examiner is respectfully requested to allow claims 62, 63, 72-74, 77-85, the currently pending claims. Claims 1-61, 64-71, and 75-76 are canceled without prejudice to refilling of the original scope. Claims 62, 81 and 82 are amended. Applicants respectfully request reconsideration of the rejections.

Applicants have amended claims 62, 81 and 82 to correct minor grammatical errors, and antecedent support, as recited in the Advisory Action.

The Advisory Action has stated that the previous amendments to the claims would overcome the prior art rejection. Applicants respectfully submit that the present claims are in form for allowance. In view of the cancellation of Claim 59, there is no need to rejoin the non-elected species, and thus no additional search or consideration is required.

# CONCLUSION

Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, she is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number CELL-017.

Respectfully submitted,

Date: Sept. 2, 2003

By: Pamela J. Sherwood  
Pamela J. Sherwood, Ph.D.  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231